Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin for post-stroke lower limb spasticity
ACTRN12617001603303Phase 3Not yet recruiting
- Sponsor
- The Hospital Research Foundation Group
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lower extremity spasticity comparing Botulinum toxin injection + physiotherapy with Placebo injection + physiotherapy (2 arms). Primary endpoints: Gait velocity and 2-minute walking distance. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
lower extremity spasticity
Beyond the preview
Go deeper on ACTRN12617001603303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001603303.